Indeed the first licensed gene therapy medicine alipogene tiparvovec (Glybera) is an AAV1 vector carrying human lipoprotein lipase (LPL), to be injected intramuscularly for the treatment of patients with LPL deficiency. This evidence concerns the gene LPL and hyperinsulinemic hypoglycemia, familial, 4.